Ipilimumab panel rescheduled for February

FDA's Oncologic Drugs Advisory Committee will meet on Feb. 9 to discuss a BLA from Bristol-Myers Squibb Co. (NYSE:BMY) for ipilimumab to treat metastatic melanoma. The committee had been scheduled to ...